Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Rosemonde Mandeville M.B., Ch.B., Ph.D. serves as Chief Scientific Officer of Phagelux, Inc. Dr. Mandeville has been Chairperson of Biophage Pharma Inc. since May 24, 2005 and serves as its Chief Executive Officer and Chief Scientific Officer. Dr. Mandeville served as the Chairman of Biophage Pharma Inc. until November 2004 and served as its President. She has been a Director of Biophage Pharma Inc., since October 26, 2001. Dr. Mandeville serves as Director of Investment Quebec, La Financière du Quebec, Centre des Biosciences de l'INRS/IAF and the Armand-Frappier Foundation. Dr. Mandeville has been a Director of Datex Billing Services Inc., since 2004. She served as a Director of Montec Holdings Inc. (alternatively Datex Technologies Corporation) since 2004 until January 30, 2009. She served as a Member of the Scientific Advisory Board at Biophage Pharma Inc. She served as a Professor of Immunology at Institute Armand Frappier, Université du Québec, in Montreal. She is the author of 75 publications and 185 communications in peer-reviewed international journals and is the author of six books. During her distinguished career as a professor of immunology at Institute Armand Frappier, Université du Québec, in Montreal, Dr. Mandeville supervised 27 Master degree and PhD students, 13 post-doctoral fellows and 36 undergraduate students. Dr. Mandeville received her Medical Degree from the University of Alexandria, Egypt and her Ph.D. from the University of Manitoba.
Dr. Rosemonde's resaerch interests include Pharmaceutics, Biopharmaceutics, Immunology, Nanobiopharmaceutics and Nanotechnology applications in Medicine
Baccar H*, Mejri MB, Prehn R, del Campo FJ, Baldrich E, Rosemonde M, Abdelghani A
Research Article: J Nanomed Nanotechnol 2014, 5:243